Investigation of the effect of trehalose on Parkinson disease

Investigation of the effect of trehalose on motor and non-motor symptoms of Parkinson disease patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041407N10

Enrollment

Registered

2024-08-25

Start date

2024-10-06

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson`s disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Trehalose 10 g per day for 12 weeks, made by Shaanxi Fruiterco Biotechnology Co.,Ltd. Intervention 2: Control group: Placebo (one sachet of sucrose per day for 12 w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suffering from Parkinson disease Stage 1 or 2 of Parkinson`s disease (according to Hoen and Yahr scale) Satisfaction for participation in the research project Ability to read

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Assessment the severity of disease. Timepoint: At baseline and after 3 months. Method of measurement: Using Unified Parkinson's disease rating scale (UPDRS).;Assessment of non-motor symptoms. Timepoint: At baseline and after 3 months. Method of measurement: Using non-motor scale (NMS).;Quality of life. Timepoint: At baseline and after 3 months. Method of measurement: Using Parkinson`s disease quality of life -39 (PDQ-39).;Serum level of a-Synuclein. Timepoint: At baseline and after 3 months. Method of measurement: Blood Test.	—

Measure

Time frame

Assessment the severity of disease. Timepoint: At baseline and after 3 months. Method of measurement: Using Unified Parkinson's disease rating scale (UPDRS).;Assessment of non-motor symptoms. Timepoint: At baseline and after 3 months. Method of measurement: Using non-motor scale (NMS).;Quality of life. Timepoint: At baseline and after 3 months. Method of measurement: Using Parkinson`s disease quality of life -39 (PDQ-39).;Serum level of a-Synuclein. Timepoint: At baseline and after 3 months. Method of measurement: Blood Test.

—

Secondary

Measure	Time frame
Assessment the stage of Parkinson`s disease. Timepoint: At baseline and after 3 months. Method of measurement: Using Hoehn and Yahr Scale.;Assessment the depression and anxiety of patients. Timepoint: At baseline and after 3 months. Method of measurement: Using depression anxiety stress scale (DASS).;Assessment the cognition in Parkinson`s disease. Timepoint: At baseline and after 3 months. Method of measurement: Mini-Mental State Examination (MMSE).;Need to increase the dose or change the previous treatment. Timepoint: After 3 months. Method of measurement: After physical examination of patient and according to the physician`s advice.	—

Measure

Time frame

Assessment the stage of Parkinson`s disease. Timepoint: At baseline and after 3 months. Method of measurement: Using Hoehn and Yahr Scale.;Assessment the depression and anxiety of patients. Timepoint: At baseline and after 3 months. Method of measurement: Using depression anxiety stress scale (DASS).;Assessment the cognition in Parkinson`s disease. Timepoint: At baseline and after 3 months. Method of measurement: Mini-Mental State Examination (MMSE).;Need to increase the dose or change the previous treatment. Timepoint: After 3 months. Method of measurement: After physical examination of patient and according to the physician`s advice.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026